Review Article

A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD

Newaz Hossain, Pushpjeet Kanwar, and Smruti R. Mohanty

Department of Gastroenterology, New York Methodist Hospital, Brooklyn, NY 11215, USA

Correspondence should be addressed to Smruti R. Mohanty; srm9006@nyp.org

Received 15 October 2015; Accepted 27 January 2016

Academic Editor: Paolo Gionchetti

Copyright © 2016 Newaz Hossain et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the western world with prevalence of 20–33%. NAFLD comprises a pathological spectrum. Nonalcoholic fatty liver (NAFL) is at one end and consists of simple hepatic steatosis. On the contrary, nonalcoholic steatohepatitis (NASH) consists of steatosis, inflammation, and ballooning degeneration and can progress to cirrhosis. Despite the rising incidence, definitive treatment for NAFLD, specifically NASH, has not yet been established. Lifestyle modification with dietary changes combined with regular aerobic exercise, along with multidisciplinary approach including cognitive behavior therapy, has been shown to be an effective therapeutic option, even without a significant weight loss. Pioglitazone and vitamin E have shown to be most effective in NASH patients. Surgery and weight loss medication are effective means of weight loss but can potentially worsen NASH related fibrosis. Other agents such as n-3 polyunsaturated fatty acids, probiotics, and pentoxifylline along with herbal agent such as milk thistle as well as daily intake of coffee have shown potential benefits, but further well organized studies are definitely warranted. This review focuses on the available evidence on pharmaceutical and nonpharmaceutical therapy in the treatment and the prevention of NAFLD, primarily NASH.

1. Introduction

Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver disease characterized by macrovesicular fatty infiltration, inflammation, and hepatocytes ballooning injury. It has become the most common cause of liver disease and abnormal liver function test in industrialized countries [1, 2] with a prevalence of 20 to 33% [3, 4]. There is lower prevalence and lower degree of liver cell injury in African American population while higher prevalence is reported in Asians and Hispanics with advanced grade of liver damage compared to other ethnicities [5]. Approximately 30% of patients with simple steatosis or nonalcoholic fatty liver (NAFL) will eventually develop nonalcoholic steatohepatitis (NASH) [6, 7], while 15–25% of NASH patients will eventually progress to cirrhosis and 30–40% of cirrhotic patients will die due to liver related complications [8]. Most common cause of death in patients with NAFLD is cardiovascular disease, followed by extra hepatic cancer, with the third being liver disease [9–11].

Pathophysiology of NAFLD is still unclear; however, knowledge about pathophysiology would help understand potential therapies. Pathogenesis is believed to be largely due to liver insults starting with development of insulin resistance in patients with central adiposity or metabolic syndrome risk factors. This insulin resistance leads to increased serum free fatty acids (FFA) that causes lipogenesis in the liver and thus leads to hepatic steatosis [12]. Transformation from simple steatosis to steatohepatitis is unclear, but many complex mechanisms have been hypothesized which work in conjunction with hepatic necroinflammation and ballooning in steatotic livers. Circulating FFA activate number of intrinsic and extrinsic pathways leading to activation of proapoptotic proteins that lead to oxidative stress and apoptosis, eventually causing NASH.

Patients with NAFLD often remain asymptomatic and therefore most of them are undiagnosed for many years until eventually progressing to advanced fibrosis or cirrhosis and hepatocellular carcinoma. However, patients may sometimes present with vague right upper quadrant pain, hepatomegaly, and normal or high alanine transaminase (ALT) and usually have risk factors for metabolic syndrome. Up to 70–80% of individuals with NAFLD have insulin resistance or metabolic

...
syndrome [13]. Although NASH is associated with risk factors of metabolic syndrome such as diabetes and obesity, thin patients with normal waist circumferences can also have NASH but they usually present with higher ALT levels [14]. There is no optimal ALT level to predict the extent of NASH and advanced fibrosis [15], but NAFLD is the most common cause of incidental elevation in liver enzymes [16]. However, laboratory testing and radiological imaging cannot differentiate NASH from NAFLD. Abdominal ultrasound is most commonly used to detect liver echogenicity, but it is highly operator dependent and lacks diagnostic sensitivity [17]. Currently, gold standard for diagnosis of NASH is liver biopsy, but it is invasive in addition to having high probability of sampling error [18]. Although noninvasive methods such as NAFLD fibrosis score, FIB-4, NAFCIC score, and HAIR score as well as imaging modalities such as transient elastography are useful diagnostic methods for evaluating steatohepatitis or fibrosis [19], liver biopsy is still the definitive diagnostic method for confirming a diagnosis of NASH.

Despite growing understanding of the global epidemic of NAFLD, there is no definite pharmacotherapy available. Only proposed beneficial treatment according to available evidence is lifestyle modification with regular exercise and dietary changes or bariatric surgery in morbidly obese patients leading to gradual weight loss [20–22]. Other suggested means of pharmacological therapy are anti-inflammatory or antioxidant agents. Although insulin sensitizers such as thiazolidinediones and antioxidants such as vitamin E have shown promising results, there is some concern for associated with increased risk of fatty liver and inflammation within the hepatocytes [49]. To summarize, saturated fatty acids should be limited to 7–10% of total energy intake [42], while there should be increased consumption of food rich in mono- and polyunsaturated fatty acids. The carbohydrate intake should be limited to 40–50%, fat intake less than 30%, and protein intake 15–20% of total energy intake [50]. Additionally, fructose rich diet and additives such as monosodium glutamate should be avoided.

Dietary modification such as caloric restriction as well as carbohydrate and fat restrictions may help with improvement in liver enzymes, metabolic risk factors and hepatic steatosis.

2.2. Dietary Modification. It is important to recognize the role of nutritional imbalance between saturated and unsaturated fatty acids, as well as carbohydrates and proteins, in development and progression of NAFLD. Studies show that dietary deficiency of polyunsaturated fatty acids (PUFA) can lead to NAFLD [40] and patients with NASH seem to have overall decreased intake of PUFA and increased intake of saturated fat [41] and trans fatty acids [42]. Furthermore, fructose is another common ingredient used as sweetener in many food products and soft drinks, which is found to have a strong association with development of metabolic risk factors and 3-3-fold increased risk of developing liver steatosis [43–45]. In a recent questionnaire study involving 427 patients with NAFLD, increased consumption of fructose was significantly associated with higher stage of hepatic fibrosis while in the older aged group (>48 years old) it was also associated with higher rate of hepatic inflammation and ballooning [46]. On the contrary, oligofructose (subgroup of inulin, which is not digested in the upper GI tract) consumption has the potential to cause weight loss and decrease inflammation of hepatocytes, as seen in a randomized double-blind, placebo-controlled trial, involving 48 healthy adults who received 21 grams of oligofructose daily versus placebo for 12 weeks [47]. On the other end of dietary habit spectrum, protein deficiency and malnutrition have also been shown to cause NASH [48]. Another culprit used as an additive to enhance flavor, monosodium glutamate, has also been shown to be associated with increased risk of fatty liver and inflammation in the hepatocytes [49]. To summarize, saturated fatty acids should be limited to 7–10% of total energy intake [42], while there should be increased consumption of food rich in mono- and polyunsaturated fatty acids. The carbohydrate intake should be limited to 40–50%, fat intake less than 30%, and protein intake 15–20% of total energy intake [50]. Additionally, fructose rich diet and additives such as monosodium glutamate should be avoided.

Dietary modification such as caloric restriction as well as carbohydrate and fat restrictions may help with improvement in liver enzymes, metabolic risk factors and hepatic steatosis.
Table 1: Summary of treatment options for NAFL/NASH.

| Treatment strategy | Medication/intervention | Comment |
|--------------------|-------------------------|---------|
| **Lifestyle modification** | | |
| Weight loss | | 5–10% weight loss can lead to biochemical and histological improvement [24, 25]|
| Hypocaloric diet alone | | Better response when combined with exercise and reduced carbohydrate and fat [54, 55]|
| Dietary composition | | Diet should include addition of PUFA and decreased saturated and trans fatty acids [40–42]. Mediterranean diet has shown improvement in ALT, insulin levels, and histological markers [59, 60]|
| Exercise alone | | Effective even without weight loss [38, 61]|
| Diet plus exercise | | Greatest beneficial effect [24, 64, 65]|
| Bariatric surgery | | Could be beneficial in reversing NASH [22, 66]; some studies show worsening fibrosis [67, 68]|
| Orlistat | | Not enough evidence to support or oppose its use|
| Sibutramine | | FDA withdrew sibutramine from market due to cardiovascular events|
| **Insulin sensitivity** | | |
| Thiazolidinediones | | For patients with NASH, they improve insulin resistance, biomarkers, steatosis, and inflammation [69, 70]; caution should be taken in regard to cardiovascular risks|
| Metformin | | It offers no additional biochemical or histological benefits|
| Meglitinides and incretin mimetics | | GLP-1 analog has shown histological improvement in phase 2 trial [71]|
| **Antilipidemic** | | |
| Statins | | Decrease in transaminases, possible role in delaying progression from NAFL to NASH; safe to use in patients with NAFL and NASH|
| Fenofibrate | | Possible increased mortality risk in NAFLD patients|
| Niacin | | May be hepatotoxic|
| NPC1L1 inhibitor | | Not enough evidence to support or oppose its use|
| n-3 polyunsaturated fatty acids | | May help reverse NAFLD according to some studies [72, 73]|
| **Antioxidants** | | |
| Vitamin E | | Improves histological markers in nondiabetic NASH [70]; may have greater benefit when combined with other agents [74–76]; may be associated with increased risk for cardiovascular events and prostate cancer|
| SAM, NAC, and betaine | | Not enough evidence to support or oppose its use|
| **Anti-inflammatory** | | |
| Pentoxifylline | | May improve liver enzymes and histology [77]|
| **Probiotics** | | May improve liver enzymes, insulin resistance, and anti-inflammatory markers [78, 79]|
| **Cytoprotective and antiapoptotic agents** | | |
| Ursodeoxycholic acid | | May improve liver enzymes and histology, but further well-designed studies are needed|
| **Other** | | |
| RAAS | | Small studies show improvement in liver enzymes and histology, but larger randomized controlled studies are warranted|
| Coffee | | Coffee is associated with decreased prevalence of NAFLD and may have a role in delaying progression of fibrosis [80]|
| Vitamin D | | Replacement does not show improvement [81]|
| Phlebotomy | | Not enough evidence to support or oppose its therapeutic use|
| **Herbal** | | |
| Milk thistle | | May improve liver chemistry and histology especially in combination with other agents such as vitamin E and phospholipids [82, 83]|

NASH: nonalcoholic steatohepatitis; PUFA: polyunsaturated fatty acids; FDA: Food and Drug Administration; NAFL: nonalcoholic fatty liver; NAFLD: nonalcoholic fatty liver disease; NPC1L1: Niemann-Pick CI-Like 1; SAM: S-adenosyl methionine; NAC: N-acetyl cysteine; RAAS: Renin-Angiotensin-Aldosterone System.

There is no consensus on the exact amount of calorie restriction that is required to achieve enough weight loss to have an effective response on NAFLD. Weight loss achieved through caloric restriction leads to reduced liver size and fat content [51] and may be able to reverse hepatic steatosis [52] and lead to overall histological improvement [30]. Studies on the effect of hypocaloric diet are small and nonrandomized and lack histological analysis and thus we cannot be assured regarding the benefits from such an approach [35, 53]. Few studies have evaluated the role of weight loss through dietary modification with focus on restricting carbohydrate and fat component. In one study, 170 overweight or obese subjects were randomized to either reduced carbohydrate or reduced fat diet for 6 months along with total calorie restricted diet
(30% less energy intake/day) for all participants [54]. Both groups had decreased body weight, total body fat, visceral fat, and intrahepatic lipid content with no significant difference between the two groups. Similarly, a study of 59 women with NAFLD, randomized to low fat versus low carbohydrate diet for 6 months, showed that both groups had weight loss (5.5% and 5.7%, resp.) and both led to decreased liver enzymes [55]. There were no significant differences between the groups. Therefore, these studies suggest that hypocaloric diet, when combined with reduced carbohydrate or fat component, has a greater benefit in improving intrahepatic lipid content and liver enzymes.

Different dietary options with balanced macronutrient composition have been studied because of their effect on insulin resistance, weight loss, and lipid profile. Mediterranean diet consisting of nuts, fruits, vegetables, olive oil, fish, legumes, and so forth has been shown to reduce risk of metabolic syndrome, major cardiovascular events, and total mortality [56–58]. In one study including 73 patients with a diagnosis of NAFLD and 58 healthy controls, the relationship of NAFLD severity with adherence to Mediterranean diet was evaluated [59]. There was a significant negative correlation between adherence to Mediterranean diet and ALT, insulin levels, stage of fibrosis, severity of steatosis, and the likelihood of having NASH. Similarly, a randomized study comparing Mediterranean-like diet with diet consisting of 50–60% carbohydrate, 15–20% protein, and total fat <30% for two years showed significantly lower insulin resistance in the Mediterranean-style diet group [60]. Therefore, Mediterranean diet has shown promising results in controlling metabolic risk factors and possibly helping reverse steatosis in NAFLD patients, though further larger randomized controlled trials are needed to verify these results.

2.2. Exercise Alone. Physical activity, especially aerobic exercise, has been shown to improve steatosis and the intensity is directly related to the improvement in metabolic risk factors. In one study, 23 obese adults with sedentary lifestyle were randomly assigned to 4 weeks of aerobic exercise (cycling) versus regular stretching (placebo) [38]. In the aerobic exercise group, there was a significant reduction in mean hepatic triglyceride concentration, visceral adipose tissue, and plasma free fatty acids. Similarly, another study showed the same beneficial effect with aerobic exercise over a longer duration (12 weeks) [61]. Interestingly, both of these studies showed that aerobic exercise training reduces hepatic and visceral lipids even without weight loss. Additionally, aerobic exercise is shown to be far superior to resistance training, when it comes to lowering visceral adipose tissue (VAT) [62]. However, recent studies have shown that both the intensity and regularity of exercise are critical in reversing the histology in NASH patients. In one retrospective analysis of 813 adults with biopsy proven NAFLD (data collected from Nonalcoholic Steatohepatitis Clinical Research Network), subjects were categorized into inactive, moderate, or vigorous exercise based on self-reported time spent in physical activity [63]. Histological analysis showed that neither moderate intensity nor total exercise per week was associated with lower odds of having NASH or fibrosis. Instead, vigorous exercise was associated with decreased odds of having NASH and exceeding the US guidelines of vigorous exercise was associated with decreased odds of liver fibrosis.

2.3. Dietary Modification Plus Physical Activity. Dietary modifications such as calorie restriction as well as carbohydrate and fat restriction in combination with exercise have been assessed in multiple studies and combination strategy has shown better results. In a prospective study involving 261 patients with biopsy proven NASH, lifestyle modification with hypocaloric diet and moderate intensity exercise show that weight loss of >5% was associated with reduction of NAS and 90% of the participants with >10% weight loss had resolution of NASH [25]. Additionally, weight loss correlated with improvement in liver enzymes and other metabolic risk factors. In one randomized controlled trial, 56 participants were randomly assigned to one of four groups, standard care (physician advice alone), low fat diet plus moderate exercise, moderate fat/low carbohydrate diet plus moderate exercise, or moderate exercise alone for 6 months [64]. All participants had liver biopsy before and after study. Out of the 41 patients who completed the study, 36 had NASH at baseline. All groups showed significant decrease in NAS and improvement in aminotransferases with no significant difference among the subgroups. Interestingly, majority of the population did not experience significant weight loss and in fact several participants actually gained weight and still had histological improvement. In another randomized control trial involving 31 biopsy proven NASH subjects assigned to either intense lifestyle modification including diet plus 200 minutes per week of moderate physical activity or dietary modification alone for 48 weeks [24]. Results showed that exercise and diet group had average of 9.3% weight loss versus 0.2% in the counseling group. Greater percentage (67%) of participants in the exercise group had reduction of NAS of ≥ 3 points or a posttreatment NAS of ≤2 compared to control group. There were no significant changes in the degree of hepatic fibrosis. However, this study did not have any participants with baseline advanced liver fibrosis. Nevertheless, this study showed that at least 7% weight loss is required to see a beneficial effect on liver histology. Similarly, in another study 96 overweight or obese adults with type 2 diabetes were randomly assigned to an intensive lifestyle intervention (calorie restriction and 175 minutes per week of moderate intensity physical activity) versus a control group who received education alone for 12 months [65]. Out of the 96 participants, 44% were found to have hepatic steatosis at baseline on magnetic resonance spectroscopy (MRS). Intense intervention group had significant reduction in BMI, waist circumference, weight (8.3%), total fat, and intraperitoneal fat. Compared with control group, the intensive group had significant decrease in steatosis as measured by MRS and those with >10% weight loss had even higher reduction in steatosis. Similarly, in a large study of 1,006 NAFLD patients, participants were randomly assigned to lifestyle intervention (diet and exercise) or control group for 12 months. There was significant improvement in waist circumference, BMI, ALT, metabolic markers, and homeostasis model assessment of
insulin resistance (HOMA-IR) in the intervention group [86]. In summary, combination of diet and exercise has greater benefit than diet or exercise alone. Approximately 5% to 10% weight loss with diet and exercise has been shown to have beneficial effect on insulin resistance, serum transaminases, and liver histology.

3. Bariatric Surgery

Weight loss through bariatric surgery has been proposed as a possible treatment option for nonalcoholic fatty liver disease because of its positive effect on liver histology. Nevertheless, rapid sudden weight loss such as a result of bariatric surgery may lead to progression of liver failure in some NAFLD patients [31]. Numerous studies have shown improvement of steatosis and inflammation in NAFLD patients after bariatric surgery. There is still limited data on the effectiveness of bariatric surgery in NAFLD patients mainly due to lack of randomized controlled trials. Nevertheless, there are several retrospective and prospective cohort studies that have compared liver histology and metabolic markers before and after surgery.

A French study looked at the metabolic markers and histology before bariatric surgery and 1 year and 5 years after the surgery in 381 patients with severe obesity [67]. This study showed an improvement in steatosis, ballooning, and overall NAS with significant reduction in percentage of NASH patients at 5 years compared to before surgery (27.4% to 14.2%). The resolution of NASH at 1 year was 81.3% in patients who lost greater than 5% of body weight (p < 0.00001), while there was no significant difference between 1 and 5 years. Interestingly, five years after surgery there was significant worsening of fibrosis in 19.8% of patients, but 95.7% of those with worsening fibrosis had fibrosis score ≤ F1. It is unclear as to the reason for worsening fibrosis, but point to be considered is that patients with worsening fibrosis were also those with higher BMI, steatosis, ballooning, inflammation, and more insulin resistance. Furthermore, BMI loss was not associated with fibrosis resolution. In another retrospective study, 78 morbidly obese patients underwent gastric bypass with liver biopsy performed during the surgery and after weight loss [66]. All patients had steatosis and 44.8% of them had evidence of fibrosis at baseline. Biopsy after weight loss reduction showed lower prevalence (30.8%) of hepatic fibrosis and a decrease in number of patients with NASH. In a meta-analysis, authors looked at 766 paired liver biopsies from 15 different studies [22]. The combined results showed that 91.6% of patients had improvement in steatosis, 81.3% of patients had improvement in steatohepatitis, and 65.5% of them had improvement in fibrosis, while 69.5% showed complete resolution of NASH. Although, in this meta-analysis, bariatric surgery was shown to improve or completely resolve steatosis, steatohepatitis, and fibrosis, the inclusion criteria for most of these studies were less rigorous (included observational studies) and may have potential bias (publication bias). Another Cochrane systematic review of 21 studies with histological outcomes of bariatric surgery looked at 21 prospective or retrospective cohort studies which showed improvement of steatosis or inflammation in most studies except for 4 studies that showed worsening of fibrosis [68]. Both of these systematic reviews showed improvement in liver function tests and certain risk factors for metabolic syndrome as well. Nevertheless, the fact that some studies showed worsening of liver fibrosis cannot be overlooked. Further long-term and well-designed prospective studies are needed to address these issues.

4. Weight Loss Medication

Orlistat and sibutramine have been studied as a treatment option for nonalcoholic fatty liver disease, though without much convincing results. Orlistat is a pancreatic lipase inhibitor that reduces absorption of free fatty acids [87]. Sibutramine is a centrally acting serotonin-norepinephrine reuptake inhibitor, which enhances satiety [88]. In a randomized prospective trial, 50 overweight patients with biopsy proven NASH were assigned to either 1400 kcal/day diet plus vitamin E 800 IU alone or with combination of orlistat for 9 months [89]. Both groups showed reduction in steatosis, necroinflammation, ballooning, and NAS in addition to reduction of weight and improvement in aminotransferases. However, independent of the groups, weight loss of greater than 5% led to improved insulin sensitivity and steatosis, while those that lost 9% or more of body weight had greater histological improvement. There were no significant differences between the two groups with respect to metabolic and histological markers, signifying that weight loss is responsible for histological improvement rather than the medication. In another double-blind randomized placebo-controlled trial assessing the efficacy of orlistat in 52 patients with NAFLD (40 confirmed by biopsy), individuals were randomized to orlistat versus placebo for 6 months [90]. Mean weight loss was 8% with orlistat versus 6% in placebo group (difference was not significant). ALT improved in both groups, with greater improvement in orlistat group. Statistically significant reversal of steatosis by ultrasound was seen in orlistat group. Repeat biopsy performed in subset of subjects showed that both groups had 50% improvement in steatosis without significant improvement in fibrosis and inflammation.

Conversely, sibutramine was associated with 11.4% incidence of serious nonfatal myocardial infarction and nonfatal stroke as compared to placebo in the SCOUT trial [91]. Therefore, in 2010, FDA withdrew sibutramine from the US market due to risk of serious cardiovascular events [92] and many studies with sibutramine were discontinued due to adverse effects [93].

5. Antidiabetic Medications

5.1. Thiazolidinediones. Thiazolidinediones (TZDs) are peroxisomal proliferator activated receptor- (PPAR-) gamma agonists that promote hepatic fatty acid oxidation which increases hepatic lipogenesis and insulin sensitivity [94]. Most studies have shown improved biochemical efficacy with TZDs in NAFLD patients and some of them resulted in histological improvements such as steatosis and inflammation [95]. Nevertheless, these effects of TZDs do not seem to be sustained as some studies have noticed recurrence of NASH after discontinuation of TZDs [96, 97]. Furthermore,
the important adverse effects associated with TZDs such as weight gain, edema, osteoporosis, and heart failure cannot be overlooked [97–99].

Rosiglitazone and pioglitazone are the two TZDs that have been studied the most. The FLIRT trial enrolled 63 biopsy proven NASH patients who received either rosiglitazone or placebo for 1 year [100]. Rosiglitazone was shown to improve steatosis, transaminase levels, adiponectin and insulin sensitivity, despite evidence of significant weight gain compared to placebo. There were no significant changes in fibrosis or NAS. In an open label study of 137 biopsy proven NASH subjects randomized to either rosiglitazone alone or combination of rosiglitazone and metformin versus combination of rosiglitazone and losartan for 48 weeks, there was no significant difference among the groups even though there was overall histological improvement in steatosis, inflammation, ballooning degeneration, and fibrosis as well as reduction of aminotransferase levels [101].

Pioglitazone has been studied extensively and was found to have more promising results in terms of liver enzymes and histological changes such as steatosis and inflammation. A study by Belfort et al. enrolled 55 patients with glucose intolerance or diabetes and biopsy proven NASH and assigned them to either hypocaloric diet plus pioglitazone or hypocaloric diet plus placebo for 6 months [69]. Pioglitazone group had a significant improvement in ALT, insulin sensitivity as well as steatosis, ballooning, and inflammation. Fibrosis reduction for pioglitazone group compared to placebo did not reach significance probably due to the small number of patients or short duration of study. In another randomized double-blind placebo-controlled trial with pioglitazone involving 74 nondiabetic subjects with NASH, pioglitazone group had significant improvement in hepatic cellular injury and fibrosis after 12 months of treatment [98]. The PIVENS trial is a large randomized multicenter, double-blinded, placebo-controlled study of 247 nondiabetic patients with NASH who were assigned to one of three groups: pioglitazone 30 mg daily, vitamin E 800 IU daily, or placebo [70]. The primary endpoint of the study was decrease in NAS by at least 2 points and improvement in ballooning by 1 point. Vitamin E group as compared to other groups had significantly higher percentage of subjects with improvement in NASH (p < 0.001). Although pioglitazone group failed to reach primary endpoint, both treatment groups showed significant improvement in serum aminotransferases, reduction in steatosis, and lobular inflammation, but not fibrosis score. The failure to reach primary endpoint was possibly due to more subjects in the pioglitazone group having absence of ballooning at baseline while improvement in ballooning was one of the primary outcomes. Although most studies show no effect on reduction of fibrosis, thiazolidinediones such as pioglitazone may have a role in delaying progression of fibrosis in patients with NASH [27, 102]. Therefore, overall current data suggest that thiazolidinediones may be effective in treating NASH and are associated with significant improvement in biomarkers and histological markers such as steatosis and inflammation and possibly delaying fibrosis, although effects may be reversed after discontinuation of the medication [97]. Nevertheless, caution should be taken with regard to the use of TZDs due to the known cardiovascular adverse effects.

5.2. Metformin. Metformin improves insulin resistance by reducing hepatic gluconeogenesis and fatty acid oxidation, increasing peripheral and hepatic insulin sensitivity, decreasing intestinal glucose absorption, and lowering serum lipid concentration [103]. Recent animal studies have also suggested a possible role of metformin in prevention of hepatocellular carcinoma [104, 105]. Many studies have been done assessing the effectiveness of metformin in NAFLD patients, but the results have been inconsistent. Although some of the studies showed improvement in metabolic markers, aminotransferases, and liver histology, most of the benefits may be due to metformin's known effect of causing improvement in insulin sensitivity, weight loss, and other markers of metabolic syndrome [106, 107]. A randomized controlled trial involving 110 nondiabetic NAFLD patients for 12 months compared three groups: metformin, vitamin E, and prescriptive diet. It showed that metformin treatment is better than a prescriptive diet or vitamin E in terms of improvement in aminotransferases [108]. Histological analysis also showed modest improvement in hepatic steatosis and inflammation. On the contrary, other randomized controlled trials have failed to show histological benefit with metformin. Clearly, most studies show that metformin offers no additional histological or biochemical benefit other than its independent effect on insulin sensitivity and weight loss and therefore metformin is not recommended as first line treatment for nonalcoholic fatty liver disease [21].

5.3. Other Antidiabetic Agents. Studies have been done with meglitinides and incretin mimetics (GLP-1 analogs) to assess their effect on fatty liver. Meglitinide stimulates pancreatic insulin release and pancreatic beta cell growth. The data on use of meglitinide as treatment for NAFLD/NASH is scarce. Although some of the pilot studies involving these agents have shown improvement in metabolic biomarkers and histology, these studies involved very small sample sizes [109–111]. In a phase 2 trial with liraglutide (GLP-1 analog), 52 overweight subjects with NAS were randomly assigned to liraglutide versus placebo group [71]. Of the patients in liraglutide group, 39% had resolution of NASH compared to 9% in the placebo group. Only 9% of patients in the liraglutide group had worsening of fibrosis compared to 26% in the placebo group, which indicates a possible role of liraglutide in treating NASH and possibly delaying progression of fibrosis.

6. Antilipidemic Drugs

6.1. Statins. Lipid lowering drugs such as statins, niacin, fibric acid derivatives, ezetimibe, and n-3 PUFA have been studied for patients with hyperlipidemia and NAFLD (see Table I). Dyslipidemia is one of the cardiovascular risk factors and an important component of metabolic syndrome which is a risk factor for NAFLD [112]. Although many studies with statins and NAFLD have been done, most of them lacked histological evaluation. Statin's beneficial effect on NAFLD
has been proposed to be likely due to its anti-inflammatory, antioxidant, and antifibrinogenic properties [113, 114]. In a recent cross-sectional study, data analysis of 2578 patients who underwent liver ultrasound showed that 35.3% of them had hepatic steatosis while 990 subjects were either past or current user of statins [115]. Patients with BMI >27.5 kg/m² and statin use for >2 years were associated with three times lower prevalence of steatosis.

Studies on efficacy of simvastatin have been inconsistent as in one study there was an improvement in serum ALT [116], while in another study there was no improvement in aminotransferases or histology [117]. In a multicenter, randomized, double-blind, placebo-controlled trial, 326 subjects with hyperlipidemia and chronic liver disease (NAFLD = 209 and hepatitis C = 117) were randomly assigned to either 80 mg of pravastatin or placebo for 36 weeks [118]. Compared to placebo, pravastatin was found to lower the lipid panel without causing significant changes in ALT. Studies involving atorvastatin have also shown significant decrease in aminotransferases, lipid levels [119, 120], and steatosis [121], while also delaying progression of NAFL to NASH [122]. In a randomized controlled trial involving patients with ultrasonographic evidence of NAFLD and hyperlipidemia, 63 subjects were assigned to 20 mg a day of atorvastatin, 62 subjects assigned to 200 mg a day of fenofibrate, and 61 subjects with combination of fenofibrate and atorvastatin [123]. The atorvastatin alone group and the combination group had a higher degree of biochemical improvement and ultrasonographic regression of NAFLD compared to fenofibraté alone. Therefore, most studies show consistency in improvement in transaminases while some show possible role in reversing steatosis and delaying progression of NAFLD to NASH. Overall, literature and guidelines support the use of statins in patients with NAFLD and hyperlipidemia [21].

6.2. Fibrates. Fibrates activate PPAR alpha and lipoprotein lipase and suppress apolipoprotein [124]. The evidence of beneficial effect of fibrates as a therapy for NAFLD is not sufficient. In a study of 40 patients with biopsy proven NASH (n = 24) and NAFL (n = 16) who were given 200 mg a day of fenofibrate for 48 weeks, there was significant improvement in triglycerides, alkaline phosphatase, gamma-glutamyl transpeptidase, and grade of ballooning degeneration [125]. However, there was no improvement in insulin resistance, transaminases, hepatic steatosis, necroinflammation, or fibrosis. In another randomized controlled trial, 46 patients with NASH were assigned to either 600 mg a day of gemfibrozil (n = 23) or placebo (n = 23) [126]. The treatment group had significantly lower liver enzymes, but no significant histological changes. The results of studies with fenofibrate as a therapeutic option for NAFLD are inconsistent. In fact, one study even found fenofibrate to cause increase in mortality from coronary heart disease compared to placebo, although the difference was not significant [127]. Total mortality was also slightly higher in the fenofibrate group compared to the placebo group (7.3% versus 6.6%; p = 0.18).

6.3. Niacin. Niacin has been suggested to prevent hepatic steatosis in experimental mice models [128]. However, in a randomized controlled double-blind trial involving 27 obese patients with NAFLD who underwent treatment with fenofibrate versus niacin versus placebo, both treatment groups failed to show any decrease in intrahepatic triglycerides [129]. Furthermore, some data actually showed niacin to have adverse hepatotoxic effect, ranging from mild elevation in aminotransferases to fulminant hepatic failure [130–132].

6.4. Niemann-Pick C1-Like 1 (NPC1L1) Inhibitor. In multiple studies, ezetimibe (NPC1L1 inhibitor) has been shown to improve biochemical parameters and histological markers of NAFLD [116, 133, 134], but most studies either lacked the control group or involved a small sample size. A recent randomized controlled trial involving 32 biopsy proven NAFLD patients given either 10 mg/day of ezetimibe or placebo for 6 months showed that ezetimibe group had significant improvement in ballooning score and fibrosis stage compared to the control group but did not have significant change in inflammation, steatosis, and overall NAS [135]. Nevertheless, this study also showed that ezetimibe was associated with significant increase in hepatic long-chain fatty acids, oxidative stress, insulin resistance, and HbA1c, which are known to be associated with development and progression of NAFLD.

6.5. Polyunsaturated Fatty Acids (PUFA). Omega-3 belongs to a broader group of fats called polyunsaturated fatty acids (PUFA) that have been studied extensively as a treatment option for NAFLD. Studies have shown that NAFLD is associated with decreased hepatic PUFA [40, 136]. In one study involving 144 patients with NAFLD and hyperlipidemia, subjects were randomized to receive American Heart Association (AHA) diet plus PUFA versus AHA diet and placebo for 24 weeks [72]. In the PUFA group, there was complete regression of steatosis in 19.7% of patients and overall reduction of steatosis in 53.03% of patients along with significantly greater improvement in ALT compared to diet alone. More recently, in a double-blind randomized placebo-controlled clinical trial involving diabetic patients, 37 subjects with biopsy proven NASH were randomized to PUFA or placebo for 48 weeks [137]. The primary outcome for this study was improvement of NAS ≥2 points. Liver biopsy was done before and after completion of study. Surprisingly, in the placebo group, there was significant improvement in hepatic steatosis and NAS but worsening of lobular inflammation, whereas in the PUFA group, there was worsening of insulin resistance and there were no significant histological changes. Therefore, PUFA may not be a good option for patients with NASH and diabetes. Another double-blind, randomized, placebo-controlled trial with similar primary endpoint involved 34 subjects with biopsy proven NASH who were randomized to n-3 fish oil 3000 mg/day versus placebo for 1 year [73]. At the end of study, 4 of the 17 subjects in the treatment group...
and 3 of the 17 subjects in the placebo group had reduction in NAS of ≥2 points with no difference between the groups after adjusting for weight loss and other variables. Further studies with larger sample size are required to arrive at a firm conclusion regarding the beneficial effect of n-3 PUFAs.

7. Antioxidants

7.1. Vitamin E. Vitamin E has been shown to improve aminotransferases as well as histological markers in subjects with NASH (see Table 1). Some studies have also shown complete resolution of steatohepatitis, but there are mixed results on its effect on liver fibrosis. As described above in the pioglitazone section, the PIVENS trial, a randomized, multicenter, double-blind, placebo-controlled trial [70] showed that vitamin E when compared to placebo led to significantly higher rate of improvement in necroinflammation (43% versus 19%), although there was no significant improvement in fibrosis. Therefore, vitamin E can be used as treatment for non-diabetic NASH, but caution should still be taken as some studies show that vitamin E is associated with overall increased cardiovascular mortality [21,138,139] as well as increased risk of prostate cancer [140].

The effect of vitamin E on NAFLD has also been evaluated in many combination therapy studies. In a prospective, double-blind, randomized, placebo-controlled trial, 45 patients with biopsy proven NASH were enrolled to receive either vitamin E 1000 IU plus vitamin C 1000 mg or placebo for 6 months [74]. At the end of treatment, the vitamin E + C group had statistically significant improvement in fibrosis but no improvement in necroinflammation and ALT. Similar results were seen in a small study evaluating combination of vitamin E and pioglitazone compared to vitamin E alone [75]. In another combination study involving vitamin E with ursodeoxycholic acid (UDCA), 48 patients with biopsy proven NASH were randomly assigned to either UDCA + vitamin E or UDCA or placebo for two years [76]. Serum aminotransferases and steatosis improved significantly in the combination group compared to UDCA alone and placebo. Therefore, overall vitamin E shows histological beneficial effect on non-diabetic NASH subjects but also may have some additional benefits when combined with other agents, such as antioxidants, anti-inflammatory, and insulin sensitizing agents. Nevertheless, further studies with longer duration of treatment are necessary to conclude the therapeutic beneficial effect of vitamin E and its various combinations with other agents.

7.2. Other Antioxidants. Changes in methionine/folate metabolism may contribute to the development of steatosis [141]. S-adenosyl methionine (SAM) and betaine are nutritional supplements that have anti-TNF-alpha, cytoprotective, anti-apoptotic, and antisteatogenic activity and can cause reversal of insulin resistance [142, 143]. N-acetyl cysteine (NAC) is a glutathione precursor which increases glutathione in hepatocytes and limits the reactive oxygen species that causes hepatocellular injury [144]. Most studies involving these antioxidants have either a short duration or a small sample size. Further larger studies with longer duration treatment and histological analysis are required to confirm a beneficial effect of these antioxidants on NAFL/NASH.

8. Anti-Inflammatory Agents

Pentoxifylline is a xanthine derivative that inhibits TNF-alpha, which is a proinflammatory cytokine that has been shown to activate reactive oxygen species by lipid peroxidation and promote necroinflammation, fibrogenesis, hepatic insulin resistance, and apoptosis [145]. In a randomized placebo-controlled trial, 49 patients with biopsy proven NASH were randomized to pentoxifylline versus placebo for 1 year [77]. All patients in the treatment group had either improved NAS or no change. Compared to placebo, pentoxifylline group had significant improvement in ALT, steatosis, inflammation, and fibrosis but no change in ballooning. A decrease in NAS of ≥2 was seen in 50% of patients in pentoxifylline group versus 15.4% in placebo group. Additionally, 25% of NASH patients in the pentoxifylline group had resolution of NASH at the end of treatment. On the contrary, another randomized controlled trial of 30 patients with biopsy proven NASH failed to show any significant difference in improvement in aminotransferases and histology compared to placebo, although there was improvement in both parameters compared to baseline [146]. A recent meta-analysis showed that pentoxifylline significantly reduced serum aminotransferase, BMI, fasting glucose, steatosis, lobular inflammation, and fibrosis, but larger well-designed, randomized, placebo-controlled trials are still needed to confirm these results [147].

9. Probiotics

Bacterial overgrowth in the bowel is present in 50% of patients with NASH and changes in the intestinal bacterial content may be related to the pathogenesis of NASH due to enhanced intestinal permeability, activation of inflammatory cytokines, and absorption of endotoxins [148,149]. Therefore, probiotics have been suggested as a treatment option in NASH patients [150]. However, some studies have shown worsening of steatosis with the use of probiotics [151]. In a double-blind randomized controlled trial, 30 patients with NAFLD diagnosed by biopsy were randomized to either Lactobacillus bulgaricus and Streptococcus thermophilus or placebo [78]. The treatment group had significant improvement in liver enzymes. In another study, 66 patients were randomly assigned to either Bifidobacterium longum with fructooligosaccharides (Fos) plus lifestyle modification (diet and exercise) or lifestyle modification alone for 24 weeks [79]. At the end of study, compared to the lifestyle modification group, the combination treatment group caused significant reduction in TNF-alpha, CRP, AST, HOMA-IR, steatosis, and NAS. In a meta-analysis of 4 double-blind randomized trials involving 134 biopsy proven NAFL/NASH patients, the authors concluded that probiotics significantly decreased total cholesterol, aminotransferases, HOMA-IR, and TNF-alpha [152].
10. Cytoprotective and Antiapoptotic Agents

Ursodeoxycholic acid (UDCA) has a beneficial effect on hepatobiliary diseases by its cytoprotective, immunomodulatory, and antiapoptotic effects [153]. The efficacy results of UDCA on NAFLD/NASH have been mixed, with some trials showing improvement in ALT and other histological markers such as steatosis, inflammation, and fibrosis [76, 154, 155], while others show no significant difference when compared to placebo [156–158]. In a recent systematic review of 12 randomized clinical trials, UDCA monotherapy was shown to improve liver enzymes, steatosis, and fibrosis in few studies, but UDCA combined with other drugs showed greater improvements in both steatosis and inflammation [155]. Moreover, there might be variation in treatment outcome with low and high dose UDCA [154]. Further evaluation of dose-dependent outcome is necessary.

11. Other Therapeutic Agents

11.1. RAAS (Renin-Angiotensin-Aldosterone System). Emerging evidence, mainly in animal studies, has shown that inhibiting RAAS pathway decreases hepatic stellate cell activity, which in turn prevents fibrosis [159] and that ACE-inhibitors and angiotensin receptor blockers may be useful in treating NAFLD as they may lead to decreased fibrosis [160]. However, not many studies have been done in humans with NAFLD to assess the effectiveness of ACE inhibitors or angiotensin receptor blockers (ARB). In one study, 54 patients with hypertension and NASH were randomly assigned to either telmisartan or valsartan; both groups showed improvement in transaminases and insulin resistance, while telmisartan was also shown to improve NAS and fibrosis [161]. Furthermore, in a recent cross-sectional study of 290 hypertensive patients with biopsy proven NAFLD, liver histology was compared in patients with and without RAS blocker; there was significantly less ballooning and lower fibrosis stage in patients on RAAS blockers [162]. Despite the promising results, larger randomized controlled studies are required to draw a conclusion on their beneficial effect.

11.2. Coffee. Coffee is rich in sources of bioactive phytochemicals including methylxanthines (caffeine), amino acids, phenolic acids, and polyphenols which may protect against liver disease. A study involved 195 patients participating in a questionnaire about coffee and espresso as well as other caffeinated drinks and chocolate [80]. All patients underwent liver biopsies and compared to espresso, regular coffee consumption was associated with decreased odds ratio of liver fibrosis. Furthermore, espresso was associated with the presence of metabolic syndrome. Again, this study suggests possible beneficial effect of coffee and not caffeine, which is also present in espresso, but espresso failed to demonstrate the same beneficial effect. In a recent meta-analysis of 16 studies comprising 3153 cases of hepatocellular carcinoma, the risk of HCC was found to be reduced by 40% with coffee intake compared to no coffee [163]. Further well organized larger studies are required to draw any conclusion.

11.3. Vitamin D. There is not enough data assessing the effect of vitamin D supplementation on NAFLD, even though studies have shown vitamin D deficiency is associated with development of NAFLD [164, 165]. A study of 60 patients with biopsy proven NAFLD and 60 healthy controls shows that, compared to controls, NAFLD patients had a significant decrease in vitamin D levels and that levels of vitamin D also negatively correlated with histological severity of steatosis, necroinflammation, and fibrosis independent of other variables or presence of metabolic syndrome [166]. Despite multiple studies suggesting association of NAFLD with low vitamin D, supplementation has not been shown to be very promising (see Table 1). In a recent randomized, double-blind, placebo-controlled trial, 53 patients with NAFLD were given 50,000IU every two weeks or placebo for a total study duration of 4 months and the results showed no significant difference in insulin resistance, TNF-alpha, or aminotransferases [81].

11.4. Phlebotomy. Although there has been a significant recent interest in the role of iron in NAFLD, the results have been conflicting. A recent study showed that patients who were suspected to have NAFLD had higher body iron and a greater hemoglobin level [167]. Another study involving data collected from 1,201 biopsy proven adult NAFLD patients showed that although ferritin level was significantly associated with steatosis and fibrosis, it was not shown to be a good predictor of fibrosis [168]. Similar results were seen in a multicenter study involving 1014 patients with liver biopsy-confirmed NAFLD [169]. In a phase II clinical trial involving 31 patients with biopsy proven NAFLD, all subjects underwent phlebotomy to achieve ferritin level ≤50 µg/liter [170]. Repeat biopsy was done 6 months after treatment. Iron reduction correlated with significant reduction in overall NAS, although there was no significant change in the individual histological features of steatosis, inflammation, ballooning, or fibrosis. In summary, although serum ferritin seems to lack diagnostic accuracy for fibrosis, phlebotomy as a therapeutic option needs to be further studied.

11.5. Herbal Medications. Recently, herbal therapy has been studied as treatment option for NAFLD as some animal models have shown a beneficial effect of correcting markers of inflammation, metabolic risk factors, transaminases, and histological markers such as steatosis. Herbal supplements should still be cautiously used and further investigated for adverse effects prior to considering for NAFLD treatment.

Milk thistles, also known as *Silybum marianum* or silymarin, have been shown to have antioxidant, anti-inflammatory, and antifibrogenic activity along with its ability to help with liver cell regeneration [171–173]. In a randomized double-blind, controlled trial, silybin (major active constituent of silymarin) combined with vitamin E and phospholipids was shown to significantly improve steatosis [82]. Furthermore, in another multicenter, double-blind clinical trial, 138 patients were randomized to either silybin plus phosphatidylcholine or placebo for 12 months [83]. Patients receiving the combination treatment showed a significant
improvement in liver enzymes, HOMA-IR, and liver histology. Therefore, silybin as a combination treatment seems to have potential therapeutic ability, but further studies are required to assess its beneficial effect on NAFLD/NASH.

12. Upcoming Drugs

12.1. Bile Acid Receptors. Farnesoid X receptor (FXR) is a bile acid nuclear receptor that is highly expressed in the liver, intestine, kidney, and adipose tissue (see Table 2). These receptors have been proposed to have a role in development of hepatic steatosis. Stimulation of these receptors improves insulin sensitivity and decreases hepatic steatosis, inflammation, and fibrosis [174–176]. Obeticholic acid (OCA) is an FXR agonist which has been tested as a treatment option for NAFLD. In a double-blind, placebo-controlled trial, treatment with OCA for 6 weeks led to improvement in insulin sensitivity and reduction in markers of liver inflammation and fibrosis [84]. In FLINT trial, which is a multicenter, double-blind, placebo-controlled trial, 283 noncirrhotic NASH patients were randomly assigned to OCA versus placebo [85]. In this study, OCA compared to placebo group had significant improvement in aminotransferases, HOMA-IR, and all markers of NAS ($p = 0.002$). Other than worsening of lipid panel which might require addition of a statin, this study had mostly positive outcomes. In fact, the trial was stopped early because of efficacy based on the high statistically significant improvement in liver histology. A phase 3 international trial, also known as REGENERATE trial, assessing the effect of OCA on patients with NASH with advanced fibrosis [clinicaltrials.gov NCT01672879].

12.2. PPAR Alpha/Delta Agonist. Elafibranor (GFT505) is a PPAR alpha/delta agonist which has anti-inflammatory and antifibrotic properties [178] and has been shown to improve liver function and insulin sensitivity [179, 180]. In a phase 2 multicenter randomized controlled trial, 274 subjects with histologically proven NASH received either GFT505 80 mg/daily or 120 mg/daily or placebo for one year [clinicaltrials.gov NCT01694849]. Primary outcome of the study was resolution of NASH without worsening of fibrosis. Compared to placebo group, relative risk of achieving primary endpoint in the 120 mg and 80 mg arms was 1.94 ($p = 0.027$) and 1.68 ($p = 0.091$), respectively. In the 120 mg group, there were significant improvements in all histological markers including fibrosis. Additionally, compared to placebo, GFT505 leads to significant improvement in metabolic markers. This study showed that GFT505 produces a dose-dependent improvement in histology of patients with NASH. Currently, phase 3 trial with GFT505 is underway.

12.3. Other Drugs. Among the other upcoming drugs which are being studied in NASH patients is cysteamine bitartrate (see Table 2). In an open label phase 2a clinical trial involving patients with biopsy proven NAFLD with elevated aminotransferases, participants received treatment with cysteamine bitartrate for six months and result showed marked decline in ALT and AST levels in all patients as well as significant decrease in cytokeratin and increase in adiponectin levels [181]. In another phase 2 placebo-controlled trial with caspase inhibitor involving 124 patients with biopsy proven NASH, result showed improvement in ALT and cytokeratin [182]. Another new drug with great potentials includes simtuzumab, which is a monoclonal antibody against lysyl oxidase-like 2 (LOXL2) with antineoplastic activity now being investigated in clinical trials as treatment for NASH and advanced fibrosis [clinicaltrials.gov NCT01672879].

### Table 2: Summary of upcoming therapeutic agents for NAFL/NASH.

| Treatment strategy       | Medication                        | Comment                                                                 |
|--------------------------|----------------------------------|------------------------------------------------------------------------|
| Bile Acid Receptors (FXR)| OCA                              | Has been shown to improve aminotransferases, insulin resistance, and NAS but can worsen lipid panel [84, 85] |
| PPAR alpha/delta agonist | Elafibranor                       | Can improve metabolic risk factors and lead to resolution of NASH [https://clinicaltrials.gov NCT01694849] |
| Other agents             | Cysteamine bitartrate, caspase inhibitor, and simtuzumab | Had promising results in phase 2 trials and some are still undergoing clinical trials |

FXR: farnesoid receptor; OCA: obeticholic acid.
although results are inconclusive. Interestingly, coffee consumption with or without caffeine seems to have beneficial effect on nonalcoholic fatty liver disease, though most studies involved retrospective questionnaires. Furthermore, recent advances in phase 2 and 3 trials have definitely shown promising results, with few agents having the potential of becoming future therapeutic agent for NASH.

**Conflict of Interests**

The authors declare that there is no financial or other conflict of interests in relation to the content of this paper.

**References**

[1] C. K. Argo and S. H. Caldwell, "Epidemiology and natural history of non-alcoholic steatohepatitis," *Clinics in Liver Disease*, vol. 13, no. 4, pp. 511–531, 2009.

[2] J. D. Browning, L. S. Szczepaniak, R. Dobbins et al., "Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity," *Hepatology*, vol. 40, no. 6, pp. 1387–1395, 2004.

[3] L. S. Szczepaniak, P. Nurenberg, D. Leonard et al., "Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population," *American Journal of Physiology—Endocrinology and Metabolism*, vol. 288, no. 2, pp. E462–E468, 2005.

[4] G. Bedogni, L. Miglioli, F. Masutti, C. Tiribelli, G. Marchesini, and S. Bellentani, "Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study," *Hepatology*, vol. 42, no. 1, pp. 44–52, 2005.

[5] S. R. Mohanthy, T. N. Troy, D. Hsu, B. L. O’Brien, D. M. Jensen, and J. Hart, "Influence of ethnicity on histological differences in non-alcoholic fatty liver disease," *Journal of Hepatology*, vol. 50, no. 4, pp. 797–804, 2009.

[6] G. Musso, R. Gambino, and M. Cassader, "Non-alcoholic fatty liver disease from pathogenesis to management: an update," *Obesity Reviews*, vol. 11, no. 6, pp. 430–445, 2010.

[7] J. Raszeja-Wyszomirska, M. Lawniczak, W. Marlicz, J. Mieczynska-Kurtcz, and P. Milkiewicz, "Non-alcoholic fatty liver disease—new view," *Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego*, vol. 24, no. 144, pp. 568–571, 2008.

[8] J. Edmison and A. J. McCullough, "Pathogenesis of non-alcoholic steatohepatitis: human data," *Clinics in Liver Disease*, vol. 11, no. 1, pp. 75–104, 2007.

[9] M. Ekstedt, L. E. Franzén, U. L. Mathiesen et al., "Long-term follow-up of patients with NAFLD and elevated liver enzymes," *Hepatology*, vol. 44, no. 4, pp. 865–873, 2006.

[10] W. Nseir, A. Shalata, A. Marmor, and N. Assay, "Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease," *Digestive Diseases and Sciences*, vol. 56, no. 12, pp. 3439–3449, 2011.

[11] C. Söderberg, P. Stål, J. Askling et al., "Decreased survival of subjects with elevated liver function tests during a 28-year follow-up," *Hepatology*, vol. 51, no. 2, pp. 595–602, 2010.

[12] H. Malhi and G. J. Gores, "Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease," *Seminars in Liver Disease*, vol. 28, no. 4, pp. 360–369, 2008.

[13] G. Marchesini, E. Bugianesi, G. Forlani et al., "Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome," *Hepatology*, vol. 37, no. 4, pp. 917–923, 2003.

[14] E. Margariti, M. Deutsch, S. Manolakopoulos, and G. V. Papatheoeridou, "Non-alcoholic fatty liver disease may develop in individuals with normal body mass index," *Annals of Gastroenterology*, vol. 25, no. 1, pp. 45–51, 2012.

[15] S. Verma, D. Jensen, J. Hart, and S. R. Mohanthy, "Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)," *Liver International*, vol. 33, no. 9, pp. 1398–1405, 2013.

[16] P. Angulo and K. D. Lindor, "Non-alcoholic fatty liver disease," *Journal of Gastroenterology and Hepatology*, vol. 17, supplement s1, pp. S186–S190, 2002.

[17] S. Saadeh, Z. M. Younossi, E. M. Remer et al., "The utility of radiological imaging in nonalcoholic fatty liver disease," *Gastroenterology*, vol. 123, no. 3, pp. 745–750, 2002.

[18] V. Ratzin, F. Charlotte, A. Heurtier et al., "Sampling variability of liver biopsy in nonalcoholic fatty liver disease," *Gastroenterology*, vol. 128, no. 7, pp. 1898–1906, 2005.

[19] Y. Sumida, A. Nakajima, and Y. Itoh, "Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis," *World Journal of Gastroenterology*, vol. 20, no. 2, pp. 475–485, 2014.

[20] G. Musso, R. Gambino, M. Cassader, and G. Pagano, "A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease," *Hepatology*, vol. 52, no. 1, pp. 79–104, 2010.

[21] N. Chalasani, Z. Younossi, J. E. Lavine et al., "The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association," *The American Journal of Gastroenterology*, vol. 107, no. 6, pp. 811–826, 2012.

[22] R. R. Mummad, K. S. Kasturi, S. Chennareddygari, and G. K. Sood, "Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis," *Clinical Gastroenterology and Hepatology*, vol. 6, no. 12, pp. 1396–1402, 2008.

[23] G. Marchesini, M. Brizi, G. Bianchi et al., "Nonalcoholic fatty liver disease: a feature of the metabolic syndrome," *Diabetes*, vol. 50, no. 8, pp. 1844–1850, 2001.

[24] K. Promrat, D. E. Klein, H. M. Niemer et al., "Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis," *Hepatology*, vol. 51, no. 1, pp. 121–129, 2010.

[25] E. Villar-Gomez, Y. Martinez-Perez, L. Calzadilla-Bertot et al., "Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis," *Gastroenterology*, vol. 149, no. 2, pp. 367.e5–378.e5, 2015.

[26] J. D. Douketis, C. Macie, L. Thabane, and D. F. Williamson, "Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice," *International Journal of Obesity*, vol. 29, no. 10, pp. 1153–1167, 2005.

[27] G. Musso, M. Cassader, F. Rosina, and R. Gambino, "Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials," *Diabetologia*, vol. 55, no. 4, pp. 885–904, 2012.

[28] K. E. Stewart, D. L. Haller, C. Sargeant, J. L. Levenson, P. Puri, and A. J. Sanyal, "Readiness for behaviour change in non-alcoholic fatty liver disease: implications for multidisciplinary
care models,” *Liver International*, vol. 35, no. 3, pp. 936–943, 2015.

[29] A. St George, A. Bauman, A. Johnston, G. Farrell, T. Chey, and J. George, “Independent effects of physical activity in patients with nonalcoholic fatty liver disease,” *Hepatology*, vol. 50, no. 1, pp. 68–76, 2009.

[30] M. A. Huang, J. K. Greenson, C. Chao et al., “One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study,” *American Journal of Gastroenterology*, vol. 100, no. 5, pp. 1072–1081, 2005.

[31] T. Andersen, C. Glud, M.-B. Franzmann, and P. Christoffersen, “Hepatic effects of dietary weight loss in morbidly obese subjects,” *Journal of Hepatology*, vol. 12, no. 2, pp. 224–229, 1991.

[32] F. H. Luycks, C. Desaive, A. Thiry et al., “Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty,” *International Journal of Obesity*, vol. 22, no. 3, pp. 222–226, 1998.

[33] K. F. Petersen, S. Dufour, B. Befroy, M. Lehrke, R. E. Hendler, and G. I. Shulman, “Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes,” *Diabetes*, vol. 54, no. 3, pp. 603–608, 2005.

[34] A. Suzuki, K. Lindor, J. St Saver et al., “Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease,” *Journal of Hepatology*, vol. 43, no. 6, pp. 1060–1066, 2005.

[35] S. M. B. Duarte, J. Faintuch, J. T. Stefano et al., “Hypocaloric high-protein diet improves clinical and biochemical markers in patients with nonalcoholic fatty liver disease (NASH),” *Nutricion Hospitalaria*, vol. 29, no. 1, pp. 94–101, 2014.

[36] K. Hallsworth, G. Fattakhova, K. G. Hollingsworth et al., “Resistence exercise reduces liver fat and its mediators in nonalcoholic fatty liver disease independent of weight loss,” *Gut*, vol. 60, no. 9, pp. 1278–1283, 2011.

[37] J. Ibáñez, M. Izquierdo, I. Argüelles et al., “Twice-weekly progressive resistance training decreases abdominal fat and improves insulin sensitivity in older men with type 2 diabetes,” *Diabetes Care*, vol. 28, no. 3, pp. 662–667, 2005.

[38] N. A. Johnson, T. Sachinwalla, D. W. Walton et al., “Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss,” *Hepatology*, vol. 50, no. 4, pp. 1105–1112, 2009.

[39] C. S. Baba, G. Alexander, B. Kalyani et al., “Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis,” *Journal of Gastroenterology and Hepatology*, vol. 21, no. 1, pp. 191–198, 2006.

[40] C. D. Byrne, R. Olufad, K. D. Bruce, F. R. Cagampang, and M. H. Ahmed, “Metabolic disturbances in non-alcoholic fatty liver disease,” *Clinical Science*, vol. 116, no. 7, pp. 539–564, 2009.

[41] G. Musso, R. Gambino, F. De Micheli et al., “Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis,” *Hepatology*, vol. 37, no. 4, pp. 909–916, 2003.

[42] A. M. Zivkovic, J. B. German, and A. J. Sanyal, “Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease,” *The American Journal of Clinical Nutrition*, vol. 86, no. 2, pp. 285–300, 2007.

[43] A. Abid, O. Taha, W. Nseir, R. Farah, M. Grossovsk and, N. Assy, “Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome,” *Journal of Hepatology*, vol. 51, no. 5, pp. 918–924, 2009.

[44] W. Nseir, F. Nassar, and N. Assy, “Soft drinks consumption and nonalcoholic fatty liver disease,” *World Journal of Gastroenterology*, vol. 16, no. 21, pp. 2579–2588, 2010.

[45] X. Ouyang, P. Cirillo, Y. Sautin et al., “Fructose consumption as a risk factor for non-alcoholic fatty liver disease,” *Journal of Hepatology*, vol. 48, no. 6, pp. 993–999, 2008.

[46] M. F. Abdelmalek, A. Suzuki, C. Guy et al., “Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease,” *Hepatology*, vol. 51, no. 6, pp. 1961–1971, 2010.

[47] J. A. Parnell and R. A. Reimer, “Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults,” *The American Journal of Clinical Nutrition*, vol. 89, no. 6, pp. 1751–1759, 2009.

[48] I. A. Leclercq and Y. Horsmans, “Nonalcoholic fatty liver disease: the potential role of nutritional management,” *Current Opinion in Clinical Nutrition and Metabolic Care*, vol. II, no. 6, pp. 766–773, 2008.

[49] K. S. Collison, Z. Maqbool, S. M. Saleh et al., “Effect of dietary monosodium glutamate on trans fat-induced nonalcoholic fatty liver disease,” *Journal of Lipid Research*, vol. 50, no. 8, pp. 1521–1537, 2009.

[50] A. Kargulewicz, H. Stankowiak-Kulpa, and M. Grzyniswalski, “Dietary recommendations for patients with nonalcoholic fatty liver disease,” *Przeglad Gastroenterologiczny*, vol. 9, no. 1, pp. 18–23, 2014.

[51] M. C. Lewis, M. L. Phillips, J. P. Slavotinek, L. Kow, C. H. Thompson, and J. Touli, “Change in liver size and fat content after treatment with Optifast very low calorie diet,” *Obesity Surgery*, vol. 16, no. 6, pp. 697–701, 2006.

[52] K. Sebastianova, A. Santos, A. Kotronen et al., “Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans,” *American Journal of Clinical Nutrition*, vol. 96, no. 4, pp. 727–734, 2012.

[53] M. C. Elias, E. R. Parise, L. de Carvalho, D. Szejnfeld, and J. P. Netto, “Effect of 6-month nutritional intervention on non-alcoholic fatty liver disease,” *Nutrition*, vol. 26, no. 11–12, pp. 1094–1099, 2010.

[54] S. Haufe, S. Engeli, P. Kast et al., “Randomized comparison of reduced fat and reduced carbohydrate hypertolic diets on intrahepatic fat in overweight and obese human subjects,” *Hepatology*, vol. 53, no. 5, pp. 1504–1514, 2011.

[55] H. Rodríguez-Hernández, M. Cervantes-Huerta, M. Rodríguez-Moran, and F. Guerrero-Romero, “Decrease of aminotransferase levels in obese women is related to body weight reduction, irrespective of type of diet,” *Annals of Hepatology*, vol. 10, no. 4, pp. 486–492, 2011.

[56] R. Estruch, E. Ros, J. Salas-Salvadó et al., “Primary prevention of cardiovascular disease with a Mediterranean diet,” *The New England Journal of Medicine*, vol. 368, no. 14, pp. 1279–1290, 2013.

[57] M. T. Mitjavila, M. Fandos, J. Salas-Salvadó et al., “The Mediterranean diet improves the systemic lipid and DNA oxidative damage in metabolic syndrome individuals. A randomized, controlled, trial,” *Clinical Nutrition*, vol. 32, no. 2, pp. 172–178, 2013.

[58] A. Trichopoulou, T. Costacou, C. Bamia, and D. Trichopoulou, “Adherence to a Mediterranean diet and survival in a Greek population,” *The New England Journal of Medicine*, vol. 348, no. 26, pp. 2599–2608, 2003.
[59] M. D. Kontogianni, N. Tileli, A. Margariti et al., “Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease,” *Clinical Nutrition*, vol. 33, no. 4, pp. 678–683, 2014.

[60] K. Esposito, R. Marfella, M. Ciottola et al., “Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial,” *The Journal of the American Medical Association*, vol. 292, no. 12, pp. 1440–1446, 2004.

[61] G. J. van der Heijden, Z. J. Wang, Z. D. Chu et al., “A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents,” *Obesity*, vol. 18, no. 2, pp. 384–390, 2010.

[62] I. Ismail, S. E. Keating, M. K. Baker, and N. A. Johnson, “A systematic review and meta-analysis of the effect of aerobic vs. resistance exercise training on visceral fat,” *Obesity Reviews*, vol. 13, no. 1, pp. 68–91, 2012.

[63] K. D. Kistler, E. M. Brunt, J. M. Clark, A. M. Diehl, J. F. Sallis, and J. B. Schwimmer, “Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease,” *The American Journal of Gastroenterology*, vol. 106, no. 3, pp. 460–469, 2011.

[64] C. Eckard, R. Cole, J. Lockwood et al., “Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial,” *Therapeutic Advances in Gastroenterology*, vol. 6, no. 4, pp. 249–259, 2012.

[65] M. Lazo, S. F. Solga, A. Horsa et al., “Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes,” *Diabetes Care*, vol. 33, no. 10, pp. 2156–2163, 2010.

[66] M. Moretto, C. Kupski, V. D. da Silva, A. V. Padoin, and C. C. Mottin, “Effect of bariatric surgery on liver fibrosis,” *Obesity Surgery*, vol. 22, no. 7, pp. 1044–1049, 2012.

[67] P. Mathurin, A. Hollebecque, L. Arnalsteen et al., “Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease,” *Gastroenterology*, vol. 137, no. 2, pp. 532–540, 2009.

[68] N. C. Chavez-Tapia, F. I. Tellez-Avila, T. Barrientos-Gutierrez, N. Mendez-Sanchez, J. Lizardi-Cervera, and M. Uribe, “Bariatric surgery for non-alcoholic steatohepatitis in obese patients,” *The Cochrane Database of Systematic Reviews*, no. 1, Article ID CD007340, 2010.

[69] R. Belfort, S. A. Harrison, K. Brown et al., “A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis,” *The New England Journal of Medicine*, vol. 355, no. 22, pp. 2297–2307, 2006.

[70] A. J. Sanyal, N. Chalasani, K. V. Crowley et al., “Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis,” *The New England Journal of Medicine*, vol. 362, no. 18, pp. 1675–1685, 2010.

[71] M. J. Armstrong, P. Gaunt, G. P. Aithal et al., “Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study,” *The Lancet*, vol. 387, no. 10019, pp. 679–690, 2016.

[72] F.-S. Zhu, S. Liu, X.-M. Chen, Z.-G. Huang, and D.-W. Zhang, “Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia,” *World Journal of Gastroenterology*, vol. 14, no. 41, pp. 6395–6400, 2008.

[73] C. K. Argo, J. T. Patric, C. Lackner et al., “Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial,” *Journal of Hepatology*, vol. 62, no. 1, pp. 190–197, 2014.

[74] S. A. Harrison, S. Torgerson, P. Hayashi, J. Ward, and S. Schenker, “Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis,” *American Journal of Gastroenterology*, vol. 98, no. 11, pp. 2485–2490, 2003.

[75] A. J. Sanyal, P. S. Moftred, M. J. Contos et al., “A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis,” *Clinical Gastroenterology and Hepatology*, vol. 2, no. 12, pp. 1107–1115, 2004.

[76] J.-F. Dufour, C. M. Oneta, J.-J. Convers et al., “Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis,” *Clinical Gastroenterology and Hepatology*, vol. 4, no. 12, pp. 1537–1543, 2006.

[77] C. O. Zein, L. M. Yerian, P. Gogate et al., “Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial,” *Hepatology*, vol. 54, no. 5, pp. 1610–1619, 2011.

[78] R. Aller, D. A. De Luís, O. Izaola et al., “Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial,” *European Review for Medical and Pharmacological Sciences*, vol. 15, no. 9, pp. 1090–1095, 2011.

[79] M. Malaguarnera, M. Vacante, T. Antic et al., “Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis,” *Digestive Diseases and Sciences*, vol. 57, no. 2, pp. 545–553, 2012.

[80] R. Anty, S. Marjoux, A. Iannelli et al., “Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery,” *Journal of Hepatology*, vol. 57, no. 5, pp. 1090–1096, 2012.

[81] N. Sharifi, R. Amani, E. Hajiani, and B. Cheraghian, “Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial,” *Endocrine*, vol. 47, no. 1, pp. 70–80, 2014.

[82] C. Loguercio, A. Federico, M. Trappoliere et al., “The effect of a silybin-vitamin E-phospholipid complex on nonalcoholic fatty liver disease: a pilot study,” *Digestive Diseases and Sciences*, vol. 52, no. 9, pp. 2387–2395, 2007.

[83] C. Loguercio, P. Andreone, C. Brisc et al., “Silybin combined with phosphatidylcholine and vitamin e in patients with non-alcoholic fatty liver disease: a randomized controlled trial,” *Endocrine*, vol. 47, no. 1, pp. 70–80, 2014.

[84] S. Mudalier, R. R. Henry, A. J. Sanyal et al., “Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease,” *Gastroenterology*, vol. 145, no. 3, pp. 1574.e1–1582.e1, 2013.

[85] B. A. Neuschwander-Tetri, R. Loomba, A. J. Sanyal et al., “Farnesoid X nuclear receptor agonist obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial,” *The Lancet*, vol. 385, pp. 956–965, 2015.

[86] W.-H. Sun, M.-Q. Song, C.-Q. Jian et al., “Lifestyle intervention in non-alcoholic fatty liver disease in Chengyang District, Qingdao, China,” *World Journal of Hepatology*, vol. 4, no. 7, pp. 224–230, 2012.

[87] R. Guerciolini, “Mode of action of orlistat,” *International Journal of Obesity and Related Metabolic Disorders*, vol. 21, supplement 3, pp. S12–S23, 1997.
hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial,” *Hepatology*, vol. 46, no. 5, pp. 1453–1463, 2007.

[119] V. G. Athyros, K. Tziomalos, T. D. Gossios et al., “Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis,” *The Lancet*, vol. 376, no. 9756, pp. 1916–1922, 2010.

[120] E. Gómez-Domínguez, J. P. Gisbert, J. A. Moreno-Monteagudo, L. García-Buey, and R. Moreno-Otero, “A pilot study of atorvastatin treatment in dyslipidemia, non-alcoholic fatty liver patients,” *Alimentary Pharmacology & Therapeutics*, vol. 23, no. 11, pp. 1643–1647, 2006.

[121] M. Kiyici, M. Gulten, S. Gurel et al., “Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis,” *Canadian Journal of Gastroenterology*, vol. 17, no. 12, pp. 713–718, 2003.

[122] W. Samy and M. A. Hassanian, “Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin,” *Arab Journal of Gastroenterology*, vol. 12, no. 2, pp. 80–85, 2011.

[123] V. G. Athyros, D. P. Mikhailidis, T. P. Didangelo et al., “Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study,” *Current Medical Research and Opinion*, vol. 22, no. 5, pp. 873–883, 2006.

[124] J.-C. Fruchart and P. Duriez, “Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism,” *Drugs of Today*, vol. 42, no. 1, pp. 39–64, 2006.

[125] C. Fernández-Miranda, M. Pérez-Carreras, F. Colina, G. López-Alonso, C. Vargas, and J. A. Solis-Herruzo, “A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease,” *Digestive and Liver Disease*, vol. 40, no. 3, pp. 200–205, 2008.

[126] M. Basaranoglu, O. Acbay, and A. Sonsuz, “A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis,” *Journal of Hepatology*, vol. 31, no. 2, p. 384, 1999.

[127] A. Keech, R. J. Simes, P. Barter et al., “Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial,” *The Lancet*, vol. 366, no. 9500, pp. 1849–1861, 2005.

[128] S. H. Ganji, G. D. Kukes, N. Lambrecht, M. L. Kashyap, and V. S. Kamanna, “Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease,” *American Journal of Physiology—Gastrointestinal and Liver Physiology*, vol. 306, no. 4, pp. G320–G327, 2014.

[129] E. Fahbrini, B. S. Mohammed, K. M. Korenblat et al., “Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 95, no. 6, pp. 2727–2735, 2010.

[130] T. A. Dalton and R. Berry, “Hepatotoxicity associated with sustained-release niacin,” *The American Journal of Medicine*, vol. 93, no. 1, pp. 102–104, 1992.

[131] J. A. Etchason, T. D. Miller, R. W. Squires et al., “Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin,” *Mayo Clinic Proceedings*, vol. 66, no. 1, pp. 23–28, 1991.

[132] S. P. Lawrence, “Transient focal hepatic defects related to sustained-release niacin,” *Journal of Clinical Gastroenterology*, vol. 16, no. 3, pp. 234–236, 1993.

[133] M. Enjoji, K. MacHida, M. Kohjima et al., “NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease,” *Lipids in Health and Disease*, vol. 9, article 29, 2010.

[134] H. Park, T. Shima, K. Yamaguchi et al., “Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease,” *Journal of Gastroenterology*, vol. 46, no. 1, pp. 101–107, 2011.

[135] Y. Takeshita, T. Takamura, M. Honda et al., “The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial,” *Diabetologia*, vol. 57, no. 5, pp. 878–890, 2014.

[136] J. Araya, R. Rodrigo, L. A. Videla et al., “Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease,” *Clinical Science*, vol. 106, no. 6, pp. 635–643, 2004.

[137] S. Dasarathy, J. Dasarathy, A. Khiyami et al., “Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis,” *Journal of Clinical Gastroenterology*, vol. 49, no. 2, pp. 137–144, 2015.

[138] G. Bjelakovic, D. Nikolova, L. L. Gluud, R. G. Simonetti, and C. Gluud, “Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis,” *The Journal of the American Medical Association*, vol. 297, no. 8, pp. 842–857, 2007.

[139] E. R. Miller III, R. Pastor-Barriuso, D. Dalal, R. A. Riemsma, L. J. Appel, and E. Guallar, “Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality,” *Annals of Internal Medicine*, vol. 142, no. 1, pp. 37–46, 2005.

[140] E. A. Klein, I. M. Thompson Jr., C. M. Tangen et al., “Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT),” *The Journal of the American Medical Association*, vol. 306, no. 14, pp. 1549–1556, 2011.

[141] C. H. Halsted, J. A. Villanueva, and A. M. Devlin, “Folate deficiency, methionine metabolism, and alcoholic liver disease,” *Alcohol*, vol. 27, no. 3, pp. 169–172, 2002.

[142] M. F. Abdelmalek, P. Angulo, R. A. Jorgensen, P. B. Sylvestre, and K. D. Lindor, “Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study,” *The American Journal of Gastroenterology*, vol. 96, no. 9, pp. 2711–2717, 2001.

[143] E. Kathirvel, K. Morgan, G. Nadgiri et al., “Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine,” *American Journal of Physiology—Gastrointestinal and Liver Physiology*, vol. 299, no. 5, pp. G1068–G1077, 2010.

[144] A. Pastor, P. S. Collado, M. Almar, and J. González-Galleto, “Antioxidant enzyme status in biliary obstructed rats: effects of N-acetylcysteine,” *Journal of Hepatology*, vol. 27, no. 2, pp. 363–370, 1997.

[145] D. Pessayre, B. Fromenty, and A. Mansouri, “Mitochondrial dysfunction, methioninemetabolism, and alcoholic liver disease,” *The American Journal of Physiology—Gastrointestinal and Liver Physiology*, vol. 299, no. 5, pp. G1068–G1077, 2010.

[146] S. Kamanna, “Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease,” *Antioxidant Enzyme Status in Biliary Obstructed Rats: Effect of N-Acetylcysteine*, vol. 29, no. 3, pp. 102–104, 1992.

[147] J. A. Etchason, T. D. Miller, R. W. Squires et al., “Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin,” *Mayo Clinic Proceedings*, vol. 66, no. 1, pp. 23–28, 1991.
M. K. Munshi, M. N. Uddin, and S. S. Glaser, "The role of the renin-angiotensin system in liver fibrosis," *Experimental Biology and Medicine*, vol. 236, no. 5, pp. 557–566, 2011.

E. F. Georgescu, R. Ionescu, M. Niculescu, L. Mogoanta, and L. Vancica, "Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis," *World Journal of Gastroenterology*, vol. 15, no. 8, pp. 942–954, 2009.

G. B. Goh, M. R. Pagadala, J. Dasarathy et al., "Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease," *Liver International*, vol. 35, no. 3, pp. 979–985, 2015.

F. Bravi, C. Bosetti, A. Tavani, S. Gallus, and C. La Vecchia, "Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis," *Clinical Gastroenterology and Hepatology*, vol. 11, no. 11, pp. 1413–1421.e1, 2013.

M. Eliades and E. Spyrou, "Vitamin D: a new player in non-alcoholic fatty liver disease?" *World Journal of Gastroenterology*, vol. 21, no. 6, pp. 1718–1727, 2015.

M. Eliades, E. Spyrou, N. Agrawal et al., "Meta-analysis: vitamin D and non-alcoholic fatty liver disease," *Alimentary Pharmacology & Therapeutics*, vol. 38, no. 3, pp. 246–254, 2013.

G. Targher, L. Bertolini, L. Scala et al., "Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease," *Nutrition, Metabolism, and Cardiovascular Diseases*, vol. 17, no. 7, pp. 517–524, 2007.

C.-H. Bai, M.-S. Wu, E. Owaga, S.-Y. Cheng, W.-H. Pan, and J.-S. Chang, "Relationship between hemoglobin levels and risk for suspected non-alcoholic fatty liver in Taiwanese adults," *The Chinese Journal of Physiology*, vol. 57, no. 5, pp. 286–294, 2014.

M. Yoneda, E. Thomas, Y. Sumida et al., "Clinical usage of serum ferritin to assess liver fibrosis in patients with non-alcoholic fatty liver disease: proceed with caution," *Hepatology Research*, vol. 44, pp. E499–E502, 2014.

P. Angulo, J. George, C. P. Day et al., "Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with non-alcoholic fatty liver disease," *Clinical Gastroenterology and Hepatology*, vol. 12, no. 7, pp. 1163.e1–1169.e1, 2014.

M. D. Beaton, S. Chakrabarti, M. Levstik, M. Speechley, P. Marotta, and P. Adams, "Phase II clinical trial of phlebotomy for non-Alcoholic fatty liver disease," *Alimentary Pharmacology & Therapeutics*, vol. 37, no. 7, pp. 720–729, 2013.

J. Feher and G. Lengyel, "Silimycin in the treatment of chronic liver diseases: past and future," *Orvosi Hetilap*, vol. 149, no. 51, pp. 2413–2418, 2008.

S. J. Schreiber, Z. Wen, M. Vourvahis et al., "The pharmacokinetics of silimycin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity," *Drug Metabolism and Disposition*, vol. 36, no. 9, pp. 1909–1916, 2008.

M. Trappoliere, A. Caliguri, M. Schmid et al., "Silybin, a component of silymarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells," *Journal of Hepatology*, vol. 50, no. 6, pp. 1102–1111, 2009.

L. Adorini, M. Pruzanski, and D. Shapiro, "Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis," *Drug Discovery Today*, vol. 17, no. 17-18, pp. 988–997, 2012.

M. Dufier, K. Hörth, R. Wagner et al., "Bile acids acutely stimulate insulin secretion of mouse β-cells via farnesoid X receptor activation and K ATP channel inhibition," *Diabetes*, vol. 61, no. 6, pp. 1479–1489, 2012.

X. Xiong, X. Wang, Y. Lu et al., "Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice," *Journal of Hepatology*, vol. 60, no. 4, pp. 847–854, 2014.

 Intercept Pharmaceuticals Announces Pivotal Phase 3 Clinical Trial of Obeticholic Acid in NASH, 2015, http://ir.interceptpharma.com/releasesdetail.cfm?ReleaseID=913794.

B. Staels, A. Rubenstrunk, B. Noel et al., "Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis," *Hepatology*, vol. 58, no. 6, pp. 1941–1952, 2013.
[179] B. Cariou, R. Hanf, S. Lambert-Porcheron et al., "Dual peroxisome proliferator-activated receptor \(\alpha/\delta\) agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects," *Diabetes Care*, vol. 36, no. 10, pp. 2923–2930, 2013.

[180] B. Cariou, Y. Zaïr, B. Staels, and E. Bruckert, "Effects of the new dual PPAR\(\alpha/\delta\) agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism," *Diabetes Care*, vol. 34, no. 9, pp. 2008–2014, 2011.

[181] R. Dohil, S. Schmeltzer, B. L. Cabrera et al., "Enteric-coated cysteamine for the treatment of paediatric non-alcoholic fatty liver disease," *Alimentary Pharmacology & Therapeutics*, vol. 33, no. 9, pp. 1036–1044, 2011.

[182] V. Ratziu, M. Y. Sheikh, A. J. Sanyal et al., "A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis," *Hepatology*, vol. 55, no. 2, pp. 419–428, 2012.